News – Page 604 – Endpoints News

Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?

4 years ago

Bristol Myers takes a swing at 'off-the-shelf' cell therapies in $150M cash licensing pact with Century

4 years ago

Bristol Myers to spend $50B on deals, buybacks in next 3 years — although BD chief notes finding the right deal ...

4 years ago

Continuing push beyond Covid-19 vaccines, Moderna partners with 'CAR-M' biotech on in vivo cancer cell therapies

4 years ago

Make or break for Biogen: How the national coverage decision for amyloid-targeted Alzheimer’s drugs will shake out

4 years ago

Takeda kicks off JPM week with M&A — buying out another gamma/delta spinout and diving into a new ‘swim lane’

4 years ago

Allogene wins a major reprieve for its leading off-the-shelf cell therapy pipeline

4 years ago

Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

4 years ago

FDA approves potential blockbuster insomnia drug, a first for Swiss biotech Idorsia

4 years ago

How durable is durable? BioMarin gears up to bring hemophilia A gene therapy to FDA again with 2-year data

4 years ago

In $900M+ deal, rare disease biotechs team up on RNA therapies for CNS developmental disorders

4 years ago

Pfizer, the new master of mRNA delivery, teams up with Beam to ship base editors straight to target tissues

4 years ago

Bayer jumps on board Mammoth's ultra-small CRISPR tech with sights set first on the liver

4 years ago

Three AI deals kick off #JPM22 weekend; Can Silicon Valley change how science gets funded?; Special report: 2021 new ...

4 years ago

Digital doctors’ message to pharma marketers: Lay off email deluge and ramp up custom content

4 years ago

A new startup thinks it's found a key to drugging 'disordered' proteins — and it has plenty of cash to get started

4 years ago

Anacor veterans raise $80M in bid to tackle rare lung disease with boron-based inhibitors

4 years ago

Cytokinetics gets the Royalty treatment, snagging up to $450M to support closely watched heart programs

4 years ago

Merck revs up dealmaking engine ahead of #JPM22, inking collaborations with AI protein design player Absci

4 years ago

ALS player Amylyx bags $190M as it sets sail on Nasdaq amid choppy waters

4 years ago

Regeneron hands off ex-US rights for cholesterol disorder drug to rare disease specialist Ultragenyx

4 years ago

Fujifilm Diosynth adds on at its NC hub, bolstering lab space with plans to bring on 145 new jobs

4 years ago

How family and science moved Exelixis' new CMO to work on oncology blockbusters; While John Maraganore racks up the ...

4 years ago

Aligos crumbles after axing lead asset, as analysts rue another flop in 'beaten-down' sector

4 years ago

First page Previous page 601 602 603604605 606 607 Next page Last page